stockrowImmunityBio, Inc.
IBRX Healthcare Biotechnology
ImmunityBio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $113.3 million, up 668.3% from fiscal 2024.
- Revenue
- +93.9%
- EPS
- −120.0%
- Free cash flow
- +13.4%
- Total debt
- +57.4%
Quarter to June 2026, against a year earlier
Follow IBRX
Alert me
ImmunityBio, Inc. (IBRX) Current ratio
ImmunityBio, Inc.'s current ratio at the end of the quarter to 30 June 2026 was 5.7×, up 0.6× from fiscal 2025 (5.1×). Over the past ten years it has ranged from 0.3× (fiscal 2022) to 48.4× (fiscal 2015); the current reading is higher than 73% of that period. That is above the Biotechnology industry median of 4.9× and above the Healthcare sector median of 3.1×.
Current ratio, annual
Embed this chart
Annual newest first
| Period | Current ratio | Change |
|---|---|---|
| FY2025 | 5.1× | 51.78% |
| FY2024 | 3.4× | (33.42%) |
| FY2023 | 5.0× | 1,697.58% |
| FY2022 | 0.3× | (69.02%) |
| FY2021 | 0.9× | (44.74%) |
| FY2020 | 1.6× | (66.01%) |
| FY2019 | 4.8× | 48.13% |
| FY2018 | 3.3× | (48.70%) |
| FY2017 | 6.3× | (61.16%) |
| FY2016 | 16.3× | (66.23%) |
Quarterly newest first
| Period | Current ratio | Change |
|---|---|---|
| Jun 2026 | 5.7× | (14.17%) |
| Mar 2026 | 6.7× | 30.73% |
| Dec 2025 | 5.1× | (11.59%) |
| Sep 2025 | 5.8× | 40.33% |
| 42 more quarters | Free account |
Against its own ten years
Current ratio against peers
| Company | Current ratio |
|---|---|
| SYRE Spyre Therapeutics, Inc. compare | 27.4× |
| PTGX Protagonist Therapeutics, Inc. compare | 21.7× |
| KRYS Krystal Biotech, Inc. compare | 7.9× |
| CAI Caris Life Sciences,�Inc. compare | 6.7× |
| IBRX ImmunityBio, Inc. | 5.7× |
| TGTX TG Therapeutics, Inc. compare | 4.3× |
| CYTK Cytokinetics, Incorporated compare | 3.4× |
| MDGL Madrigal Pharmaceuticals, Inc. compare | 3.1× |
| TWST Twist Bioscience Corporation compare | 2.7× |
| Biotechnology industry median | 4.9× |
| Healthcare sector median | 3.1× |
| Market median | 1.6× |
What Current ratio is
Current Ratio shows whether a company’s short-term assets are enough to cover the bills and debts it must pay within the next year.
Current Assets (Total) ÷ Current Liabilities (Total)
More on IBRX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement